Loading
Latest filing published 23 Dec 2025 for Remus Pharmaceuticals Limited, €3,543.
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Renosen Pharmaceuticals Private Limited discloses dealings in Remus Pharmaceuticals Limited to SEBI (PIT + SAST). The record holds 73 filings, for trades running from 4 September 2023 to 19 December 2025.
On the market, this insider has only ever bought: 73 purchases, €935k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2025, the count stands at 4 purchases and no sales.
The median purchase comes to €7,751. Clusters matter here: 41 out of 73 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 23 December 2025 with an open-market purchase (€3,543) in Remus Pharmaceuticals Limited. Between a trade and the moment it shows up on SEBI (PIT + SAST), the median delay is 1 day. Until a filing is published, the market cannot know about the trade. Source: insider filings from SEBI (PIT + SAST). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 73 declarations